


Supplementary Material to "Safety and Efficacy of Elosulfase Alfa in Australian Patients with Morquio A Syndrome: A Phase 3b Study"



Supplementary file 4. Individual normalized urine keratan sulfate data (uKS) at baseline and at 25 weeks and 49 weeks follow-up. The different lines represent different patients. Ages at baseline are indicated in the legend for each patient